U.S. Markets closed

Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 8.5%

Zacks Equity Research

Progenics Pharmaceuticals, Inc. (PGNX) was a big mover last session, as the company saw its shares rise over 8% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $4.14 to $4.67 in the past one-month time frame, showed a pick-up yesterday at $4.60.

In the last 30 days, this company did not witness any estimate revisions and the Zacks Consensus Estimate has remained unchanged. However, yesterday’s price action is encouraging, so make sure to keep a close watch on this firm in the near future.

Progenics Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Other attractive players in the healthcare industry include Mallinckrodt plc (MNK), carrying a Zacks Rank #1 (Strong Buy) along with Akorn, Inc. (AKRX) and Dr. Reddy's Laboratories Ltd. (RDY) with a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 DaysClick to get this free report >>

PROGENICS PHARMA INC (PGNX): Free Stock Analysis Report

MALLINCKRODT PUBLIC LTD CO (MNK): Free Stock Analysis Report

AKORN INC (AKRX): Free Stock Analysis Report

DR REDDY'S LAB LTD ADR (RDY): Free Stock Analysis Report

Zacks Investment Research